US4395409A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Carbamoyloxyamino-1,4-benzodiazepines and medicaments containing these compounds
Assignee: Hoechst AG
•
Filing: 1981-06-02
•
Granted: 1983-07-26
•
Expires: 2001-06-02
Abstract
Abstract What are disclosed are 1,4-benzodiazepines, having a carbamoyloxyamino group, of the following formula I <IMAGE> (I) tautomers thereof of the following formula IA <IMAGE> (IA) physiologically tolerated salts thereof, said compounds having an anxiolytic action without sedating, a process for the preparation of these new compounds, pharmaceutical agents which contain the active compounds, and methods for treating anxiety states with said compounds.
Inventors
- 👤 Manfred Forsch
- 👤 Hermann Gerhards
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 21:40
CPC Classifications
C; C07; C07D; C07D243/00; C07D243/06; C07D243/10; C07D243/14; C07D243/16; C07D243/18; C07D243/20; A; A61; A61P; A61P25/00; A61P25/26; C07D401/00; C07D401/02; C07D401/04
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
104 words
A carbamoyloxyamino-1,4-benzodiazepine of the formula ##STR12## or of the formula ##STR13## or a physiologically tolerated salt of such a compound, wherein R 1 is halogen, nitro, or trifluoromethyl; R 2 is phenyl, pyridyl, or phenyl which is mono- or di-substituted by C 1 -C 4 alkyl, C 1 -C 4 alkoxy, hydroxy, halogen, or trifluoromethyl; R 3 is hydrogen, C 1 -C 4 alkyl, monoalkylcarbamoyloxy, or dialkylcarbamoyloxy; and R 4 is phenyl or phenyl which is mono- or di-substituted by halogen, nitro, cyano, trifluoromethyl, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, hydroxy, or dialkylamino having 1-4 carbon atoms in each alkyl.
Claim 2
Dependent Claim
104 words
A carbamoyloxyamino-1,4-benzodiazepine of the formula ##STR12## or of the formula ##STR13## or a physiologically tolerated salt of such a compound, wherein R 1 is halogen, nitro, or trifluoromethyl; R 2 is phenyl, pyridyl, or phenyl which is mono- or di-substituted by C 1 -C 4 alkyl, C 1 -C 4 alkoxy, hydroxy, halogen, or trifluoromethyl; R 3 is hydrogen, C 1 -C 4 alkyl, monoalkylcarbamoyloxy, or dialkylcarbamoyloxy; and R 4 is phenyl or phenyl which is mono- or di-substituted by halogen, nitro, cyano, trifluoromethyl, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, hydroxy, or dialkylamino having 1-4 carbon atoms in each alkyl.
Claim 3
Dependent Claim
1 words
7-Chloro-2-(3-chlorophenylcarbamoyloxyamino)-5-phenyl-3H-1,4-benzodiazepine.
Claim 4
Dependent Claim
1 words
7-Chloro-2-(3-chlorophenylcarbamoyloxyamino)-5-phenyl-3H-1,4-benzodiazepine.
Claim 5
Dependent Claim
1 words
5-(2-Chlorophenyl)-2-(3-chlorophenylcarbamoyloxyamino)-7-nitro-3H-1,4-benzodiazepine.
Claim 6
Dependent Claim
1 words
5-(2-Chlorophenyl)-2-(3-chlorophenylcarbamoyloxyamino)-7-nitro-3H-1,4-benzodiazepine.
Claim 7
Dependent Claim
1 words
7-Chloro-5-(2-chlorophenyl)-2-(3-chlorophenylcarbamoyloxyamino)-3H-1,4-benzodiazepine.
Claim 8
Dependent Claim
1 words
7-Chloro-5-(2-chlorophenyl)-2-(3-chlorophenylcarbamoyloxyamino)-3H-1,4-benzodiazepine.
Claim 9
Dependent Claim
1 words
2-(3-Chlorophenylcarbamoyloxyamino)-5-(2-fluorophenyl)-7-nitro-3H-1,4-benzodiazepine.
Claim 10
Dependent Claim
1 words
2-(3-Chlorophenylcarbamoyloxyamino)-5-(2-fluorophenyl)-7-nitro-3H-1,4-benzodiazepine.
Claim 11
Dependent Claim
1 words
2-(3-Chlorophenylcarbamoyloxyamino)-7-nitro-5-phenyl-3H-1,4-benzodiazepine.
Claim 12
Dependent Claim
1 words
2-(3-Chlorophenylcarbamoyloxyamino)-7-nitro-5-phenyl-3H-1,4-benzodiazepine.
Claim 13
Dependent Claim
1 words
7-Chloro-2-(3-chlorophenylcarbamoyloxyamino)-5-(2-fluorophenyl)-3H-1,4-benzodiazepine.
Claim 14
Dependent Claim
1 words
7-Chloro-2-(3-chlorophenylcarbamoyloxyamino)-5-(2-fluorophenyl)-3H-1,4-benzodiazepine.
Claim 15
Dependent Claim
26 words
A pharmaceutical preparation for the treatment of anxiety states comprising an anxiolytic amount of a compound as in claim 1 and a pharmaceutically acceptable carrier therefor.
Claim 16
Dependent Claim
34 words
A method for treating anxiety states in a patient in need of such treatment, which method comprises orally or parenterally administering to said patient an anxiolytic amount of a compound as in claim 1.
References Cited (Backward Citations)
US3205223A
Cited
US3268586A
Cited
US3678036A
Cited
US3649617A
Cited
US3799920A
Cited
US3896109A
Cited
US3825533A
Cited
DE2504937A1
Cited
AU476528B2
Cited
US4235897A
Cited
US4325957A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-07-25 | 1987-01-24 | 1987-07-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-07-25 | 1991-01-24 | 1991-07-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-07-25 | 1995-01-24 | 1995-07-26 | $7700.00 | Window Closed / Lapsed |